[{"id":"0b6d3060-8f22-49b8-8ccf-8539c20c6118","acronym":"","url":"https://clinicaltrials.gov/study/NCT05715398","created_at":"2023-02-08T18:00:07.082Z","updated_at":"2024-07-02T16:35:55.802Z","phase":"Phase 1/2","brief_title":"BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05715398","lead_sponsor":"Shanghai Gopherwood Biotech Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR negative","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • BR790"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-02-10"}]